{"organizations": [], "uuid": "accc5b991b0d90595923a66e72b14dd782350ae1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "", "site_section": "http://www.reuters.com/finance/personal-finance", "section_title": "Wealth, Personal Finance &amp; Money | Reuters.com", "url": "http://www.reuters.com/article/2015/10/16/astrazeneca-diabetes-idUSL8N12G0NF20151016", "country": "US", "title": "UPDATE 1-AstraZeneca diabetes drug combination faces delay after FDA rebuff", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "UPDATE 1-AstraZeneca diabetes drug combination faces delay after FDA rebuff | Reuters", "spam_score": 0.0, "site_type": "news", "published": "2015-10-16T11:22:00.000+03:00", "replies_count": 0, "uuid": "accc5b991b0d90595923a66e72b14dd782350ae1"}, "author": "Reuters", "url": "http://www.reuters.com/article/2015/10/16/astrazeneca-diabetes-idUSL8N12G0NF20151016", "ord_in_thread": 0, "title": "UPDATE 1-AstraZeneca diabetes drug combination faces delay after FDA rebuff", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "* U.S. FDA issues complete response letter for saxa/dapa\n* AstraZeneca predicted $3 bln sales for combination (Adds sales forecasts, more details on drugs and competitors)\nBy Ben Hirschler\nLONDON, Oct 16 (Reuters) - U.S. health regulators declined to approve a fixed-dose diabetes drug combination from AstraZeneca, delaying its launch and dealing a blow to an important plank of the drugmaker's business.\nAstraZeneca said on Friday it had received a so-called complete response letter from the Food and Drug Administration stating that more clinical data were required before it could approve the combination of saxagliptin and dapagliflozin.\nSuch letters typically outline concerns and conditions that must be addressed in order to gain U.S. approval and the move means AstraZeneca faces an unspecified wait in getting its potential blockbuster drug cocktail to market.\nLast year, during its defence against a $118 billion takeover attempt by Pfizer, AstraZeneca predicted the saxagliptin and dapagliflozin fixed-dose combination could generate peak annual sales of $3 billion, out of total diabetes revenue of $8 billion expected by 2023.\nShares in the company fell 1 percent in early trading on Friday, underperforming a 1 percent rise in the European drugs sector.\nAstraZeneca said the FDA wanted to see more clinical trial data from ongoing or completed studies and it might also require information from new studies.\nThe individual component drugs in the new mix are already approved and marketed for the treatment of types 2 diabetes, under the brand names Onglyza and Farxiga, and the FDA move is not expected to affect their status, the company added.\nSales of Onglyza reached $391 million in the first half of 2015, with recently launched Farxiga selling $205 million.\nOnglyza is a type of diabetes medicine known as a DPP-IV inhibitor, similar to Merck's highly successful Januvia.\nFarxiga belongs to a newer drug class called SGLT2 inhibitors, which have created great excitement since a clinical trial last month showed that Eli Lilly's Jardiance slashed deaths in patients at risk of heart attack and stroke.\n(Reporting by Ben Hirschler, editing by William Hardy and Jane Merriman)", "external_links": [], "published": "2015-10-16T11:22:00.000+03:00", "crawled": "2015-10-16T10:59:27.331+03:00", "highlightTitle": ""}